Biocryst Pharmaceuticals (BCRX) FCF Margin (2010 - 2026)

Biocryst Pharmaceuticals has reported FCF Margin for 17 years, with the latest figure at 39.89% in Q1 2026.

• For the quarter ending Q1 2026, FCF Margin fell 2099.0% year-over-year to 39.89%; the trailing twelve-month figure through Mar 2026 stood at 64.99% (up 7030.0% YoY), and the FY2025 full-year result was 39.64%, up 5143.0% from the prior year.
• FCF Margin for Q1 2026 stood at 39.89%, down from 41386.72% in the prior quarter.
• The five-year high for FCF Margin was 41386.72% in Q4 2025, with the low at 156.65% in Q1 2022.
• Historically, FCF Margin has averaged 2407.28% across 5 years, with a median of 23.37% in 2023.
• Annual changes were most pronounced in 2025 — FCF Margin jumped 4139120 bps — and 2026, when it slumped 2099 bps.
• Biocryst Pharmaceuticals' FCF Margin stood at 30.64% in 2022, then soared by 74 bps to 7.82% in 2023, then jumped by 43 bps to 4.48% in 2024, then soared by 924652 bps to 41386.72% in 2025, then plunged by 100 bps to 39.89% in 2026.
• The last three FCF Margin figures came in at 39.89% (Q1 2026), 41386.72% (Q4 2025), and 25.74% (Q3 2025), per Business Quant data.